Searcharxiv⌕ Search

arXiv subjects

Rahul Tiwari

Publications and source records attributed to Rahul Tiwari.

4 recordsLinked to original sources

Ayurvedic Rasayana Restores Lipid Homeostasis in Liver: Insights from Systems Biology Studies

MASLD and obesity characterized by hepatic lipid accumulation are known risk factors to manifest into Type 2 diabetes (T2D). Increased hepatic lipids due to interorgan cross talk leads de novo lipid synthesis which induce insulin resistance in multiple organs resulting in hyperglycemia. We evaluated two known lipid reducing Ayurvedic formulations, Arogyavardhini Rasa (AVR) and Nishamalaki Rasayana (NA), to understand their mechanistic basis. Network medicine-based analyses identified 128 phytochemicals in AVR and 182 in NA that met the predefined filtering criteria. The reported targets of both formulations showed significant network proximity to genes associated with T2D, fatty liver disease and obesity. An integrated knowledge graph linking formulations, phytochemicals, protein targets, FDA-approved drugs and disease genes enabling systems-level exploration of these relationships revealed eight targets, namely PPARA, PPARG, AKT1, SIRT1, TNF, PPARD, SERPINE1, and ACE which were common to both drugs. In the animal study, both formulations reduced high-fat-diet-associated increases in blood glucose, cholesterol, liver enzymes, macrovesicular and microvesicular hepatic steatosis. Untargeted liver metabolomics showed AVR and NA treatment restored sugar and nucleotide, pentose phosphate, bile and lipid metabolism pathways that were perturbed in response to high fat diet. Taken together, AVR and NA restored hepatic lipid homeostasis and inhibited manifestation of T2D.

q-bio.MN↗

IMPPAT 3.0: An updated FAIR database of phytochemicals and formulations of Indian Medicinal plants

Ayurvedic formulations represent a rich source of traditional knowledge, encompassing distinct therapeutic approaches, medicinal ingredients, and underlying principles of drug action. However, systematic integration of this knowledge with standardized modern biomedical terminology and resources remains limited. Here, we present IMPPAT 3.0, an updated version of the Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT: https://cb.imsc.res.in/imppat/) database that extends its scope by incorporating curated and harmonized information on Ayurvedic formulations from authoritative sources, while expanding its coverage of medicinal plants, phytochemicals, and therapeutic use terms. IMPPAT 3.0 further enriches plant and phytochemical information with annotations on clinical trials, patents, bioactivity, protein targets, spectral data, plant image links, and AyuCaRe reports. The compiled data is also organized as IMPPAT-KG, a knowledge graph that enables exploration of relationships among IMPPAT entities. We demonstrate the utility of the resource through a network medicine analysis of single herbal drugs (SHDs) reported for rheumatoid arthritis (RA), revealing significant proximity of their protein targets to RA-associated genes, and pinpointing of phytochemical pairs with potentially complementary effects on RA pathogenesis. In conclusion, by integrating traditional medicinal knowledge, IMPPAT provides a FAIR-compliant ethnopharmacological platform for systematic investigation of Indian medicinal plants and Ayurvedic formulations for drug discovery applications.

q-bio.MN↗

Democratizing Agent Deployment Safety: A Structural Monitoring Approach

AI software development agents are increasingly capable of modifying infrastructure and security critical systems, creating risks where an agent completes its assigned task while covertly weakening safeguards through actions such as broadening permissions, degrading logging, or introducing persistence mechanisms. While frontier laboratories may deploy sophisticated monitoring pipelines, many organizations and individual users adopting coding agents lack the resources and governance maturity required to maintain complex learned monitor ensembles. We study this problem as infrastructure level sabotage under task success in the infrastructure-as-code setting from ControlArena and compare trained and untrained monitors across synchronous and asynchronous deployment modes. We introduce an Information Flow Graph (IFG) monitor that analyzes structural security regressions using control-flow and data-flow graph diffs alongside raw code diffs. In asynchronous evaluation, an untrained git diff monitor misses 11.6% attacks at 1% false positive rate auditing budget, our untrained IFG monitor reduces this to 3.5%, and the trained Async RF monitor achieves below 1%. Unlike the trained Async RF monitor, IFG can also operate synchronously as a pre-deployment safeguard that blocks suspicious infrastructure changes before execution or merge. In synchronous mode, IFG realtime rollback reduces joint main task and covert task success from 74.4% to 0.0% with no measurable reduction in legitimate task completion. These results suggest that untrained structural monitors provide a practical and auditable path toward democratizing deployment safety for organizations seeking trustworthy adoption of advanced AI agents.

cs.AI↗

Computational investigation of single herbal drugs in Ayurveda for diabetes and obesity using knowledge graph and network pharmacology

Metabolic diseases such as type 2 diabetes and obesity represent a rapidly escalating global health burden, yet current therapeutic strategies largely target isolated symptoms or single molecular pathways. To this end, we developed an integrated computational pipeline leveraging knowledge graph, pathway analysis and network pharmacology to elucidate the multi-target mechanisms of Ayurvedic Single Herbal Drugs (SHDs). SHDs associated with diabetes and obesity were curated from the Ayurvedic Pharmacopoeia of India, followed by phytochemical identification using IMPPAT database, yielding a shortlist of 11 SHDs and their 188 phytochemicals after drug-likeness and bioavailability filtering. Subsequently, molecular targets of the phytochemicals in SHDs, disease-associated genes and therapeutic targets of FDA-approved drugs, were curated via integration of data from several databases. Pathway enrichment analysis revealed significant functional overlap between SHD-associated and disease-associated pathways. All curated data were embedded into a Neo4j-based knowledge graph, enabling SHD-disease intersection analysis that prioritized key disease-relevant targets, including PTPN1, GLP1R, and DPP4. Also, the SHD-Target-FDA-approved drug profile elucidated the molecular and mechanistic aspects of the SHDs as a phytochemical cocktail, and is in alignment with the clinically studied synergistic FDA-approved drug combinations. Network pharmacology based protein-protein interaction analysis identified PPARG as another central regulator. Using a quantitative framework, we identified phytochemical pairs within SHDs, which were structurally dissimilar and target-wise distinct, yet acted on shared or different disease-associated pathways, indicating complementary and potentially synergistic interactions. Molecular docking analysis of two selected druggable targets identified putative lead phytochemicals.

q-bio.MN↗